1. Introduction {#sec1-cancers-12-01313}
===============

Acute promyelocytic leukemia (APL) is a relatively rare hematologic malignancy accounting for \~10% of acute myeloid leukemia (AML) cases \[[@B1-cancers-12-01313]\]. APL is characterized by M3 morphological subclassification, t(15;17)(q22;q21) chromosomal translocation, and promyelocytic leukemia protein (PML)---retinoic acid receptor alpha (RAR~α~) gene fusion, showing high rates of complete remission (CR) and cure using front-line schedules with all-trans-retinoic acid (ATRA) and/or arsenic trioxide (ATO). Apart from the classical PML-RAR~α~ cases, some APL patients are diagnosed with rare APL variants, characterized by a different rearrangement involving RAR~α~ plus another partner gene. According to some reviews, these APL genetic variants account for \~1--2% of APL cases, but the real frequency remains unknown \[[@B2-cancers-12-01313],[@B3-cancers-12-01313],[@B4-cancers-12-01313],[@B5-cancers-12-01313]\]. To our knowledge, 14 types of variant APL where RAR~α~ is fused to different genes have been reported \[[@B2-cancers-12-01313],[@B3-cancers-12-01313],[@B4-cancers-12-01313],[@B5-cancers-12-01313],[@B6-cancers-12-01313],[@B7-cancers-12-01313],[@B8-cancers-12-01313],[@B9-cancers-12-01313],[@B10-cancers-12-01313],[@B11-cancers-12-01313],[@B12-cancers-12-01313],[@B13-cancers-12-01313],[@B14-cancers-12-01313],[@B15-cancers-12-01313],[@B16-cancers-12-01313],[@B17-cancers-12-01313],[@B18-cancers-12-01313],[@B19-cancers-12-01313],[@B20-cancers-12-01313],[@B21-cancers-12-01313],[@B22-cancers-12-01313],[@B23-cancers-12-01313],[@B24-cancers-12-01313],[@B25-cancers-12-01313],[@B26-cancers-12-01313],[@B27-cancers-12-01313],[@B28-cancers-12-01313],[@B29-cancers-12-01313],[@B30-cancers-12-01313],[@B31-cancers-12-01313],[@B32-cancers-12-01313],[@B33-cancers-12-01313],[@B34-cancers-12-01313],[@B35-cancers-12-01313],[@B36-cancers-12-01313],[@B37-cancers-12-01313],[@B38-cancers-12-01313],[@B39-cancers-12-01313],[@B40-cancers-12-01313],[@B41-cancers-12-01313],[@B42-cancers-12-01313],[@B43-cancers-12-01313],[@B44-cancers-12-01313],[@B45-cancers-12-01313],[@B46-cancers-12-01313],[@B47-cancers-12-01313],[@B48-cancers-12-01313],[@B49-cancers-12-01313],[@B50-cancers-12-01313],[@B51-cancers-12-01313],[@B52-cancers-12-01313],[@B53-cancers-12-01313],[@B54-cancers-12-01313],[@B55-cancers-12-01313],[@B56-cancers-12-01313],[@B57-cancers-12-01313],[@B58-cancers-12-01313],[@B59-cancers-12-01313],[@B60-cancers-12-01313],[@B61-cancers-12-01313],[@B62-cancers-12-01313],[@B63-cancers-12-01313]\]. Moreover, the clinical features and optimal treatment of variant APLs remain to be established. In fact, some authors have suggested resistance to ATO and ATRA for the PLZF-RAR~α~ APL, which is probably the most frequent form of rare APL forms (up to 0.8% of all APLs) \[[@B3-cancers-12-01313],[@B27-cancers-12-01313]\].

In this study, we aim to analyze the incidence, characteristics, treatment patterns, and outcomes of variant APLs reported to the PETHEMA epidemiology registry, including patients from Poland, Argentina, Portugal, and Spain from PALG (Polish Adult Leukemia Group), PETHEMA (Programa para el Tratamiento de Hemopatias Malignas), and GATLA (el Grupo Argentino de Tratamiento de la Leucemia Aguda) groups. Given the clinical heterogeneity and scarce number of variant APL patients reported in the literature, we also aim to perform a systematic review in order to shed light on strategies to improve the management of these extremely rare diseases.

2. Methods {#sec2-cancers-12-01313}
==========

2.1. Patients and Eligibility {#sec2dot1-cancers-12-01313}
-----------------------------

Between November 1996 and January 2020, adult patients from institutions from Spain, Poland, Portugal, Argentina, Colombia, and Uruguay were registered in the PETHEMA database. In all patients, the diagnosis of APL was suspected by cytomorphology and confirmed by conventional cytogenetics and/or reverse transcriptase-polymerase chain reaction (RT-PCR). Patients were reported irrespectively of the treatment administered, including also those dying early before starting ATRA or chemotherapy. Eligibility criteria and trial design for PML-RAR~α~ patients have been reported elsewhere \[[@B64-cancers-12-01313],[@B65-cancers-12-01313],[@B66-cancers-12-01313],[@B67-cancers-12-01313]\]. Patients diagnosed with rare APL variants were not eligible as per PETHEMA trial protocols, but baseline and treatment information were also collected using the same forms than for PML-RAR~α~ APLs. Diagnosis of APL variants was performed after clinical suspicion (M3 morphology and lack of genetic diagnosis of t(15;17) or PML-RAR~α~). Specific PCR tests for rare rearrangements involving RAR~α~ were performed locally according to routine clinical practice. Two central laboratories were available in Spain as per physician's demands in case of need. Informed consent was obtained from patients. According to the Declaration of Helsinki, the protocol was approved by the Research Ethics Board of each participating hospital.

2.2. Treatment {#sec2dot2-cancers-12-01313}
--------------

No specific guidelines or recommendations for front-line or salvage therapy for rare APL variants were available during the study period. If they considered appropriate, physicians could follow front-line protocols for t(15;17) APL, where induction therapy consisted of oral ATRA and intravenous idarubicin (AIDA regimen). All patients in complete remission (CR) received 3 anthracycline-based consolidation courses, which were risk-adapted since protocol LPA99. Consolidation was followed by 2 years of maintenance, as it was previously described \[[@B64-cancers-12-01313],[@B65-cancers-12-01313],[@B66-cancers-12-01313],[@B67-cancers-12-01313]\]. Since 2017, the PETHEMA guidelines recommended ATO+ATRA combination for low- and intermediate-risk t(15;17) APL.

2.3. Response Assessment {#sec2dot3-cancers-12-01313}
------------------------

Remission induction response and relapse were assessed according to the revised criteria by Cheson et al. \[[@B68-cancers-12-01313]\]. There were no guidelines or definitions for molecular remission, molecular persistence, or molecular relapse. Relapse was defined as presence of equal or more than 5% bone marrow blasts or presence of extramedullary disease. Lumbar puncture or other diagnostic tests to assess disease status were performed as per physician's judgement.

2.4. Data Collection {#sec2dot4-cancers-12-01313}
--------------------

Data were collected and registered prospectively; last patient follow-up was updated on 15 February 2020. Following data were collected at diagnosis: age, gender, ECOG score, thrombosis and bleeding, hemoglobin level, platelet count, leukocytes (WBC) count, creatinine, uric acid, urea, lactate dehydrogenase (LDH), alkaline phosphatases, total bilirubin, and albumin, triglycerides, cholesterol, bilirubin, and type of RAR~α~ rearrangement. Coagulopathy was defined as thrombocytopenia plus either: prolonged prothrombin time and/or activated partial thromboplastin; or hypofibrinogenemia and/or increased levels of fibrin degradation products or D-dimers.

2.5. Systematic Review: Search Strategy and Selection of Studies {#sec2dot5-cancers-12-01313}
----------------------------------------------------------------

In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, two independent reviewers (M.S. and P.M.) conducted this systematic review \[[@B69-cancers-12-01313]\]. The following databases were searched without restrictions: PubMed and Excerpta Medica database (EMBASE). In addition, the reference lists of important studies and reviews were hand searched. The last literature search was performed on 23 February, 2020. Similar keywords were used in different databases: acute promyelocytic leukemia and "rare" or "variant" \[Mesh\], as well as the specific fusion genes. Case reports or studies analyzing a series of patients with rare APL variants were selected. Our systematic search obtained 60 citations from databases and journals (58 original research/case report articles and 2 reviews). The agreement in the study selection between the reviewers was excellent (kappa = 0.97).

3. Results {#sec3-cancers-12-01313}
==========

3.1. Patients and Eligibility {#sec3dot1-cancers-12-01313}
-----------------------------

Overall, 2961 patients with newly diagnosed APL from Spain, Portugal, Argentina (GATLA group), Uruguay, Colombia, and Poland (PALG group) were reported to the PETHEMA registry. Of them, 66 were coded as lack of genetic diagnosis, resulting in 2895 patients with genetically confirmed APL. Among those, 11 patients with variant APL were identified (0.4%): 9 PLZF-RAR~α~ (0.3%) and 2 NPM1-RAR~α~ (0.1%). The main characteristics of variant APL patients are presented in [Table 1](#cancers-12-01313-t001){ref-type="table"}. Briefly, the majority were men (9/11), with median age at diagnosis of 44.6 years (3 months to 76 years) in PLZF-RAR~α~ and 7 and 74 years for NPM1-RAR~α~ patients (two pediatric patients overall). Median WBC at diagnosis was 16.8 × 10^9^/L, with 50% patients classified as high-risk according to Sanz's relapse-risk score \[[@B10-cancers-12-01313],[@B11-cancers-12-01313],[@B13-cancers-12-01313]\]. Three out of 10 patients (30%) had hyperleukocytic forms with WBC \> 50 × 10^9^/L. Two out of 11 patients had therapy-related APL secondary to colon neoplasm's chemotherapy or to methotrexate plus antipaludic drugs for rheumatoid arthritis. The majority of variant APL had coagulopathy at diagnosis (6 out of 7 with available data), and 2 out of 6 patients with CD56 blast expression available were positive.

3.2. Treatment and Outcomes {#sec3dot2-cancers-12-01313}
---------------------------

All patients received induction treatment, consisting of ATRA plus idarubicine (IDA) according to the ongoing PETHEMA trial (AIDA regimen) in 5 patients, AML-type chemotherapy plus ATRA in 3 patients (1 patient IDICE, 1 patient 3 + 7, and 1 patient AIE) ([Table 1](#cancers-12-01313-t001){ref-type="table"}). Three remaining patients received an AML-type chemotherapy without ATRA or ATO (2 patients 3 + 7, and 1 patient FLUGA). CR was achieved in 8 patients (73%), with 1 resistance and 2 induction deaths (18%) (76 and 43 years old, both treated with AIDA and with WBC \> 10 × 10^9^/L and coagulopathy at presentation). The initially resistant patient received second-line regimen with AIDA (partial remission) and reached a first CR after a 2 + 5 regimen (Ida + Ara-C).

Post-remission schedule consisted of ATRA and anthracycline-based consolidation cycles in 4 patients (3 of them followed by ATRA plus low-dose chemotherapy maintenance) and intermediate or high dose Ara-C-based (HD-Ara-C) consolidation in 5 patients. Two patients (40 and 50 years old) received an allogeneic hematopoietic stem cell transplant (alloHSCT) in first CR. Only one patient (0.3 years old) received central nervous system (CNS) prophylaxis as part of the front-line regimen.

With a median follow-up of 60 months (8--101 months), 8 patients (73%) were alive at the time of analysis (3 deaths: 2 induction deaths and 1 death due to disease progression after third relapse). Overall, 4 out of 9 patients (43%) achieving first CR subsequently relapsed at 9, 24, 40, and 58 months (3 of them had CNS relapse). Patients relapsing had 53, 100, and 248 × 10^9^/L WBC counts at diagnosis (1 patient no available data). A second CR was achieved in all cases (salvage therapy was ATRA + ATO in 3 patients; and HD-Ara-C in 1; including triple intrathecal chemotherapy for all patients with CNS relapse). An alloHSCT was performed in second CR in 1 patient who relapsed subsequently, and 1 patient was planned to undergo Haploidentical alloHSCT.

3.3. Systematic Literature Review {#sec3dot3-cancers-12-01313}
---------------------------------

### 3.3.1. PLZF-RAR~α~ APL {#sec3dot3dot1-cancers-12-01313}

Chen et al. described in 1993 the first variant APL with t(11;17)(q23;q21), producing the promyelocytic leukemia zinc finger PLZF-RAR~α~ fusion gene \[[@B61-cancers-12-01313]\] (also known as ZBTB16-RAR~α~). In a multicenter study performed by Grimwade et al., 5 out of 611 APL patients (0.8%) had the PLZF-RAR~α~ fusion gene being so far the only source to estimate the frequency of variant APLs \[[@B3-cancers-12-01313]\]. PLZF-RAR~α~ APL seems to have distinct morphological features, as compared with classical APL, being the blast nucleus regular vs. bilobed, granules are fine or absent, and there is an increased CD56 expression by flow cytometry (similar to atypical FAB M3v APL) \[[@B4-cancers-12-01313],[@B11-cancers-12-01313],[@B66-cancers-12-01313]\].

To date, 35 cases of PLZF-RAR~α~ APL have been reported ([Table 2](#cancers-12-01313-t002){ref-type="table"}). Briefly, the vast majority were men (32/35) with median age at diagnosis of 48 years (15--81 years) and median WBC 9.9 × 10^9^/L, with 14 out of 34 (41%) patients classified as high-risk according to the Sanz's relapse-risk score. Five out of 35 patients (15%) had WBC \> 50 × 10^9^/L. All patients received first induction therapy that resulted in 12 CR (34%), 18 resistances (51%), and 5 induction deaths (14%). Five patients received ATRA monotherapy (1 resistance and 4 induction deaths), 14 ATRA plus chemotherapy-based regimens (9 CR \[64%\], 4 resistances, and 1 induction death), 6 AML-type chemotherapy (2 CR and 4 resistances), 6 ATO+/-chemotherapy-based induction (6 resistances), and 4 ATO+ATRA+/-chemotherapy-based induction (1 CR and 3 resistances). Accounting for first-line and salvage induction therapy, 23 patients achieved a first CR (66%). Successful salvage induction consisted of AML-type chemotherapy in 7, ATRA plus chemotherapy in 2, ATRA monotherapy in 1, and ATO+ATRA in 1 patient. Overall, 26 patients were exposed to ATRA at any therapeutic line (CR in 14, resistance in 9 \[3 of them with signs of differentiation\], and 3 were non-evaluable because of early death) and 12 were exposed to ATO (CR in 2 and resistance in 10). Two out of 23 patients achieving a first CR received subsequently an alloHSCT. Regarding survival, seven patients were not evaluable ([Table 2](#cancers-12-01313-t002){ref-type="table"}). The median follow-up of patients alive was 17 months (21--77 months), with 14 patients (48%) alive (15 deaths: 5 induction deaths, 2 deaths without relapse, and 8 deaths after relapse). Overall, 12 out of 21 patients (57%) relapsed after first CR (no CNS relapse reported), and 4 patients received an alloHSCT in first or second CR \[[@B3-cancers-12-01313],[@B4-cancers-12-01313],[@B5-cancers-12-01313],[@B6-cancers-12-01313],[@B8-cancers-12-01313],[@B9-cancers-12-01313],[@B10-cancers-12-01313],[@B11-cancers-12-01313],[@B12-cancers-12-01313],[@B13-cancers-12-01313],[@B14-cancers-12-01313],[@B24-cancers-12-01313],[@B25-cancers-12-01313],[@B26-cancers-12-01313],[@B28-cancers-12-01313],[@B29-cancers-12-01313],[@B30-cancers-12-01313],[@B31-cancers-12-01313],[@B32-cancers-12-01313],[@B33-cancers-12-01313],[@B34-cancers-12-01313],[@B63-cancers-12-01313]\].

### 3.3.2. NPM1-RAR~α~ APL {#sec3dot3dot2-cancers-12-01313}

We identified 9 cases of NPM1-RAR~α~ ([Table 3](#cancers-12-01313-t003){ref-type="table"}), with median age at diagnosis of 12 years (2--76 years). Overall, 5 (55.6%) patients were pediatric, the majority were male (6 patients), median WBC was 15.7 × 10^9^/L, and 3 had extramedullary disease. All patients received first induction therapy that resulted in 7 CR (78%) and 2 induction deaths (22%). One patient received ATRA monotherapy (1 induction death), 6 received ATRA plus chemotherapy-based regimens (5 CR and 1 induction death), and 2 an AML-type chemotherapy (2 CR). No clinical data regarding ATO sensitivity were reported. No patients achieving a first CR received an alloHSCT. The median follow-up of patients alive was 23 months (2--46 months), with 6 patients (67%) alive (2 induction deaths, and 1 death after relapse). Overall, 4 out of 7 patients (57%) relapsed after first CR (no CNS relapse reported). One patient received an alloHSCT in second CR \[[@B3-cancers-12-01313],[@B6-cancers-12-01313],[@B35-cancers-12-01313],[@B36-cancers-12-01313],[@B37-cancers-12-01313],[@B38-cancers-12-01313],[@B39-cancers-12-01313],[@B40-cancers-12-01313],[@B41-cancers-12-01313]\].

### 3.3.3. Other Variant APL {#sec3dot3dot3-cancers-12-01313}

Overall, 35 additional APL patients with other RAR~α~ fusion genes have been reported as follow: 12 with the signal transducer and activator of transcription 5 beta (STAT5B)-RARα, 6 with Transducin β-like 1 X-linked receptor 1 (TBLR1-RARα), 5 with interferon regulatory factor 2 binding proteins 2 (IRF2P2)-RARα, 2 with factor interacting with PAPOLA and CPSF1 (FIP1L1)-RAR~α~, 2 with signal transducer and activator of transcription 3 (STAT3)-RAR~α~, 2 with BCL6 Corepressor (BCOR)-RAR~α~, and 1 case of nuclear mitotic apparatus protein 1(NuMa1)-RARα, protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha (PRKAR1A)-RARα, nucleic acid binding protein 1 (NABP1)-RARα, general transcription factor II-I (GTF2I)-RARα, trafficking From ER To Golgi Regulator (TFG)-RARα, and fibronectin Type III Domain Containing 3B (FNDC3B)-RARα ([Table 4](#cancers-12-01313-t004){ref-type="table"}) \[[@B7-cancers-12-01313],[@B15-cancers-12-01313],[@B16-cancers-12-01313],[@B17-cancers-12-01313],[@B18-cancers-12-01313],[@B19-cancers-12-01313],[@B20-cancers-12-01313],[@B21-cancers-12-01313],[@B22-cancers-12-01313],[@B23-cancers-12-01313],[@B24-cancers-12-01313],[@B43-cancers-12-01313],[@B44-cancers-12-01313],[@B45-cancers-12-01313],[@B46-cancers-12-01313],[@B47-cancers-12-01313],[@B48-cancers-12-01313],[@B49-cancers-12-01313],[@B50-cancers-12-01313],[@B51-cancers-12-01313],[@B52-cancers-12-01313],[@B53-cancers-12-01313],[@B54-cancers-12-01313],[@B55-cancers-12-01313],[@B56-cancers-12-01313],[@B57-cancers-12-01313],[@B58-cancers-12-01313],[@B59-cancers-12-01313],[@B60-cancers-12-01313]\]. Male predominance was noted (25 patients), with variable age at presentation (median 43 years), in 15 out of 30 patients (50%) with WBC \> 10 × 10^9^/L. IRF2P2-RAR~α~ APL had different features at diagnosis (3 out 5 cases were female and all patients had WBC counts \< 5 × 10^9^/L).

No CRs after ATRA or ATO-based regimens were observed among 2 patients with STAT3---RAR~α~ \[[@B54-cancers-12-01313]\] or 1 with GTF2I-RAR~α~ \[[@B55-cancers-12-01313]\].

ATRA monotherapy or combined with chemotherapy was the most frequent treatment for TBLR1-RAR~α~ APL, observing 2 out of 5 CRs and frequent relapse (including 1 extramedullary). The ATO-based regimen was successfully administered in 1 case at relapse \[[@B43-cancers-12-01313],[@B44-cancers-12-01313],[@B45-cancers-12-01313],[@B46-cancers-12-01313]\].

Among STAT5B-RAR~α~ APL, treatment consisted of intensive chemotherapy plus ATRA (in most patients), with 8 out of 12 (67%) CRs and frequent relapse reported \[[@B7-cancers-12-01313],[@B15-cancers-12-01313],[@B16-cancers-12-01313],[@B17-cancers-12-01313],[@B18-cancers-12-01313],[@B19-cancers-12-01313],[@B20-cancers-12-01313],[@B21-cancers-12-01313],[@B22-cancers-12-01313],[@B23-cancers-12-01313],[@B24-cancers-12-01313],[@B49-cancers-12-01313]\].

No resistances to ATRA plus chemotherapy induction were observed among patients with IRF2P2-RAR~α~, FIP1L1-RAR~α~, BCOR-RAR~α~, NuMa-RAR~α~, PRKAR1A-RAR~α~, FNDC3B-RAR~α~, TFG-RAR~α~, and NABP1-RAR~α~, but relapses were also frequent among these settings \[[@B47-cancers-12-01313],[@B48-cancers-12-01313],[@B49-cancers-12-01313],[@B50-cancers-12-01313],[@B51-cancers-12-01313],[@B52-cancers-12-01313],[@B53-cancers-12-01313],[@B56-cancers-12-01313],[@B57-cancers-12-01313],[@B58-cancers-12-01313],[@B59-cancers-12-01313],[@B60-cancers-12-01313]\].

4. Discussion {#sec4-cancers-12-01313}
=============

This study shows that variant APL is probably less frequent (0.4%) than previously reported (1--2%). Our systematic literature search found 60 manuscripts on this topic (58 original reports and 2 reviews), almost equaling the number of patients with variant APL reported to date (*n* = 79). The characteristics of new 11 variant APL cases registered by the PETHEMA group are in line with prior reports (male predominance, PLZF-RAR~α~ as more frequent rearrangement). The vast majority of PETHEMA patients were treated with ATRA-containing schedules. While survival and CR rates seem better in our series as compared to background literature, prevention of relapse (especially in the CNS) remains as a challenging issue as well. Although prognosis of variant APLs seems better than non-promyelocytic AML, it is worse than PML-RAR~α~ APLs, where ATO + ATRA or AIDA-based regimens results in virtual absence of remission induction resistance, low rate of relapses (\<15%), and higher rates of cure (\>80%) \[[@B1-cancers-12-01313]\].

As far as we know, this is the larger series analyzing the frequency of variant APL (0.4%); 11 out of 2895 patients with genetically confirmed APL had PLZF-RAR~α~ (0.3%) or NPM1-RAR~α~ (0.1%). This frequency is lower than 1.1% previously reported by Grimwade et al. \[[@B3-cancers-12-01313]\], which showed 5 PLZF-RAR~α~ (0.8%) and 2 NPM1-RAR~α~ (0.3%) out of 611 APL. However, our frequency data should be carefully interpreted due to several reasons: (1) although the PETHEMA registry includes all suspected APL patients regardless of treatment or diagnosis, investigators may include preferably those cases evaluable for PML-RAR~α~ therapeutic protocols; (2) a number of registered APL patients were excluded from this study because of lack of genetic diagnosis. The majority of these cases had no genetic diagnosis because of very early death, but we cannot exclude that some of them had an unidentified variant APL; and (3) although the PETHEMA network offers expert counseling and possibility of genetic testing at central laboratories when required, the diagnosis of variant APL (in particular for very infrequent forms) needs first to be suspected and then guided PCR tests performed. In our opinion, the frequency of variant APL could be higher than herein reported, but probably lower than 1%.

The systematic literature review and the PETHEMA registry experience confirms some clinical features of variant APL that are common to PML-RAR~α~, as frequent coagulopathy and a median age at diagnosis of roughly 45 years old \[[@B64-cancers-12-01313],[@B65-cancers-12-01313],[@B66-cancers-12-01313],[@B67-cancers-12-01313]\]. Interestingly, one out of two NPM1-RAR~α~ patients here reported was a pediatric patient, in line with prior case reports suggesting that this form is mainly affecting children ([Table 3](#cancers-12-01313-t003){ref-type="table"}) \[[@B3-cancers-12-01313],[@B6-cancers-12-01313],[@B35-cancers-12-01313],[@B36-cancers-12-01313],[@B37-cancers-12-01313],[@B38-cancers-12-01313],[@B39-cancers-12-01313],[@B40-cancers-12-01313],[@B41-cancers-12-01313]\]. As a distinction to PML-RAR~α~ APL, our study show that variant forms present with higher median WBC counts, and 40--50% could be classified as high-risk according to the Sanz's score. As per the literature review, only IRF2P2-RAR~α~ APL had different features at diagnosis (3 out 5 cases were female and all had WBC \< 5 × 10^9^/L) ([Table 4](#cancers-12-01313-t004){ref-type="table"}) \[[@B7-cancers-12-01313],[@B15-cancers-12-01313],[@B16-cancers-12-01313],[@B17-cancers-12-01313],[@B18-cancers-12-01313],[@B19-cancers-12-01313],[@B20-cancers-12-01313],[@B21-cancers-12-01313],[@B22-cancers-12-01313],[@B23-cancers-12-01313],[@B24-cancers-12-01313],[@B43-cancers-12-01313],[@B44-cancers-12-01313],[@B45-cancers-12-01313],[@B46-cancers-12-01313],[@B47-cancers-12-01313],[@B48-cancers-12-01313],[@B49-cancers-12-01313],[@B50-cancers-12-01313],[@B51-cancers-12-01313],[@B52-cancers-12-01313],[@B53-cancers-12-01313],[@B54-cancers-12-01313],[@B55-cancers-12-01313],[@B56-cancers-12-01313],[@B57-cancers-12-01313],[@B58-cancers-12-01313],[@B59-cancers-12-01313],[@B60-cancers-12-01313],[@B61-cancers-12-01313]\]. On the other hand, it has been suggested that CD56 could be frequently expressed in some variant APL forms \[[@B2-cancers-12-01313],[@B4-cancers-12-01313]\], but this could not be confirmed in our series (CD56 available only in 5 patients).

Apart from accurate diagnosis, the main issue for the management of variant APL is the striking lack of evidence to guide therapeutic approaches in this population. Although our study aimed to shed light on this management, making reliable recommendations remains challenging in light of patient's and therapeutic approaches heterogeneity reported so far. Thus, we can only make suggestions for induction therapy, as follows: (1) a chemotherapy-based approach could be administered for STAT3-RAR~α~ and GTF2I-RAR~α~ as 3 reported cases were resistant to ATRA- or ATO-based regimens; (2) an AIDA or AIDA-like induction could be employed for NPM1-RAR~α~, IRF2P2-RAR~α~, FIP1L1-RAR~α~, BCOR-RAR~α~, NuMa-RAR~α~, PRKAR1A-RAR~α~, FNDC3B-RAR~α~, TFG-RAR~α~, and NABP1-RAR~α~ (only 1 induction resistance reported). No clinical data regarding ATO sensitivity were available in the literature for these APL forms. However, in our series, one pediatric patient achieved a second CR after ATO plus ATRA plus intrathecal therapy for a concomitant bone marrow and CNS relapse, suggesting that ATO could be active as well in NPM1-RAR~α~ APL; (3) an ATRA plus chemotherapy-based regimen could be employed for TBLR1-RAR~α~ and STAT5B-RAR~α~, but the CR rate seems much lower than in PML-RAR~α~ APL. Of note, an ATO-based salvage was successfully used in 1 patient with relapsed TBLR1-RAR~α~ APL.

Regarding treatment and outcomes of PLZF-RAR~α~ APL, previously reported cases (*n* = 35) and data from our cohort of patients (*n* = 9) allow for more reliable recommendations. Based on previously published data, induction schedules were quite heterogeneous, including some ATO-based regimens, with low CR (34%) and high resistance rates (51%). Of note, better CR rates (64%) were observed among 14 patients receiving ATRA plus chemotherapy-based induction ([Table 2](#cancers-12-01313-t002){ref-type="table"}). In contrast, front-line regimens were more homogeneous (AIDA or AIDA-like in 7 patients) in the PETHEMA cohort, no resistances occurred and early death was the only cause of induction failure, similar to PML-RAR~α~ patients \[[@B70-cancers-12-01313]\]. Until we have better evidence, it seems reasonable to recommend a first induction with AIDA or AIDA-like regimens for PLZF-RAR~α~ patients. Regarding ATO therapy, although clinical responses are disappointing, combinations including ATO could play a role at relapse, where some responses have been observed so far ([Table 1](#cancers-12-01313-t001){ref-type="table"} and [Table 2](#cancers-12-01313-t002){ref-type="table"}). The mechanism of resistance to ATRA and ATO in PLZF-RAR~α~ APL could be related to distinct nature of leukemogenic process as compared to the PML-RAR~α~. Rego et al., observed in vitro and in vivo, that therapeutic doses of ATRA and ATO can induce the degradation of both fusion protein, but maintenance of the leukemic phenotype depends on the continuous presence of the PML-RAR~α~ but not of the PLZF-RAR~α~ protein \[[@B71-cancers-12-01313]\]. According to another study, ATRA, but not ATO, can provoke degradation of the PLZF-RARA fusion protein \[[@B27-cancers-12-01313]\]. Moreover, it has been suggested that ATRA has difficulties to completely release the corepressor proteins like N-CoR (nuclear receptor corepressor) or nuclear receptor transcriptional (SMRT) from the PLZ-RAR~α~ fusion protein as there is a second binding site for corepressor complex in the PLZF region \[[@B72-cancers-12-01313]\]. We should also highlight that PML restauration by ATO and ATRA activates p53 by recruiting the protein to PML-nuclear bodies site and promoting its activation. The lack of p53 function could be in relation to the resistance that is observed in APL variants \[[@B73-cancers-12-01313]\]. On the other hand, activation of the hematopoietic growth factor granulocyte colony-stimulating factor (G-CSF) receptor signaling could lead to the release of corepressor proteins from PLZF, supporting the therapeutic combination of ATRA and G-CSF \[[@B12-cancers-12-01313]\]. Other studies provided biological rationale to enhance the efficacy of ATRA through combinations with interferon \[[@B74-cancers-12-01313]\] or histone deacetylase inhibitors \[[@B75-cancers-12-01313],[@B76-cancers-12-01313]\] and efficacy of ATRA and ATO through 8-CPT-CAMP \[[@B77-cancers-12-01313],[@B78-cancers-12-01313]\]. We should mention the possibility of using tamibarotene instead of ATRA for those patients with variants since it is thought that tamibarotene is a better inducer of differentiation and cells death in APL cells \[[@B79-cancers-12-01313]\].

Post-remission outcomes were worse in variant APL as compared to classical forms, mainly due to frequent relapses. In the literature cases, crude relapse rate was 57% among PLZF-RAR~α~ and NPM1-RAR~α~, even if intensive consolidations were often administered. In our short series, 43% of patients relapsed with a remarkable frequency of CNS involvement, but a second CR was achieved in all patients. It should be noted that variant APLs frequently show risk factors that have been related with an increased risk of relapse in PML-RAR~α~ APL (i.e., hyperleukocytosis and male gender) \[[@B80-cancers-12-01313]\]. In our series, 3 out of 4 relapses occurred in patients with more than 50 × 10^9^/L WBC counts at diagnosis. Given the high rate of relapses observed, we can speculate that consolidation regimens including ATRA and chemotherapy (i.e., anthracycline and Ara-C) may be useful to prevent hematological and extramedullary relapses. Regarding specific CNS prophylaxis, it is difficult to make recommendations given the low number of cases, but it seems judicious to follow similar approaches than for typical APL. Although our short but mature series shows an acceptable proportion of patients still alive (73%), better than in previously published data. We can hypothesize that more homogeneous schedules with ATRA plus chemotherapy-based regimens, successful salvages, and more contemporaneous treatments, could explain our survival results. From our experience, the role of alloHSCT in first CR is debatable, but it should be performed when possible in second CR.

In conclusion, we confirm that variant forms are very rare, accounting for less than 1% of APLs. Main characteristics of 11 patients reported by PETHEMA are in line with previous reports (male predominance, high WBC, median age 45 years, PLZF-RAR~α~ followed by NPM1-RAR~α~ as more frequent rearrangements). Except for STAT3-RAR~α~ and GTF2I-RAR~α~ APLs, ATRA plus chemotherapy-based induction may lead to high CR rates. Further studies are needed to gain insights on optimal post-remission strategies to prevent the relatively high rate of relapse observed in variant APL patients.
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cancers-12-01313-t001_Table 1

###### 

Clinical characteristics, treatment, and outcomes of 11 variant acute promyelocytic leukemia (APL) patients reported to the PETHEMA registry.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sex/Age\                   WBC\        Therapy-Related APL                  Coagulo-Pathy   CD56 %   Karyotype &\           Front-Line Therapy                                                                                                                                                                                                      Induction Response   Relapse                       Salvage Therapy                                                                       AlloHSCT (Type)             Survival in Months (Status)
  (Years)                    × 10^9^/L                                                                 Rearrangement by PCR                                                                                                                                                                                                                                                                                                                                                                                                
  -------------------------- ----------- ------------------------------------ --------------- -------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ----------------------------- ------------------------------------------------------------------------------------- --------------------------- -----------------------------
  **PLZF-RAR~α~ patients**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  M/31                       NA          No                                   NA              NA       t(11;17)(q23;q21)\     **Induction** AIDA (PETHEMA 99), **Consolidation**, **Maintenance** 6-MP/MTX/ATRA                                                                                                                                       CR                   YES (isolated CNS sarcoma)\   **ATRA + ATO + TIT---CR2, RTH**, consolidation HD-Ara-C + IDA; maintenance 6-MP/MTX   NO                          101+
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                         at 58 months                                                                                                                                    

  F/50                       2.9         Yes: MTX for arthritis               YES             100      t(11;17)(q23;q21)\     **Induction** ATRA + IDICE, **Consolidation** Ara-C/MTZ/ATRA (×2), **alloHSCT**                                                                                                                                         CR                   NO                            \-                                                                                    YES (MUD)                   36+
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                                                                                                                                                                         

  M/76                       21.4        Yes: chemotherapy for colon cancer   YES             NA       t(11;17)(q23;q21)\     **Induction** AIDA (PETHEMA2012)                                                                                                                                                                                        Death                \-                            \-                                                                                    \-                          0.3 (death)
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                                                                                                                                                                         

  M/67                       53          No                                   YES             47       t(11;17)(q23;q21)\     **Induction** AIDA (PETHEMA 2012), **Consolidations** 1st: IDA/Ara-C/ATRA, 2nd:MTZ/ATRA, 3rd: IDA/Ara-C/ATRA **Maintenance** 6-MP/MTX/ATRA (2 years)                                                                    CR                   YES (bone marrow)\            **ATRA + ATO---CR2**\                                                                 NO                          60 (death)
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                         1st at 40 months\             **2nd relapse**: MTZ + Ara-C---**CR3** consolidation Mylotarg (×2)\                                               
                                                                                                                                                                                                                                                                                                                                                                           2nd at 52 months\             **3rd relapse:** untreated                                                                                        
                                                                                                                                                                                                                                                                                                                                                                           3rd at 60 months                                                                                                                                

  M/43                       16.8        No                                   YES             0        t(11;17)(q23;q21)\     **Induction** AIDA (PETHEMA 2012)                                                                                                                                                                                       Death                \-                            \-                                                                                    \-                          0.2 (death)
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                                                                                                                                                                         

  M/40                       9.6         No                                   YES             0        t(11;17)(q23;q21)\     **Induction** ATRA + IA 3+7, **Consolidation** HD-Ara-C (×1), alloHSCT                                                                                                                                                  CR                   NO                                                                                                                  YES (MUD)                   47+
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                                                                                                                                                                         

  M/3 months                 56.4        No                                   YES             NA       t(11;17)(q23;q21)\     **Induction** ATRA + AIE + ithAra-C, **Consolidation** ATRA + AI + ithAra-C (×1) ATRA + HAM + ithAra-C (×1), **Intensification**: ATRA + HAE + ithAra-C, **Maintenance**: ATRA + 6-TG Ara-C s.c. + ithAra-C + RTH CNS   CR                   NO                            \-                                                                                    NO                          48+
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                                                                                                                                                                         

  M/33                       248         No                                   NA              NA       t(11;17)(q23;q21)\     **Induction** DA 3+7, **Consolidation** DA 3+7                                                                                                                                                                          CR                   YES (isolated CNS)\           **HD-Ara-C + TIT (×8)---CR2**, alloHSCT\                                              YES (MRD)                   62+
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                         1st at 24 months\             **2nd relapse:** Ara-C + MTZ + TIT (×7) plus radiotherapy---**CR3**\                                              
                                                                                                                                                                                                                                                                                                                                                                           2nd at 34 months\             **3rd relapse:** ATRA + FLAG-IDA---CR4\                                                                           
                                                                                                                                                                                                                                                                                                                                                                           3rd at 50 months              consolidation ATRA + ATO                                                                                          

  M/62                       1.1         No                                   NA              0        t(11;17)(q23;q21)\     **Induction** IA 3+7 (×2), **Consolidation** HD-Ara-C (×2)                                                                                                                                                              CR                   NO                            \-                                                                                    NO                          8+
                                                                                                       PLZF-RAR~α~                                                                                                                                                                                                                                                                                                                                                                                                         

  **NPM1-RAR~α~ patients**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  F/7                        100         No                                   NA              NA       t(5;15;17)\            **Induction** AIDA (PETHEMA 2017), **Consolidation**: 1st: IDA/Ara-C/ATRA, 2nd: MTZ/ATRA, 3rd: IDA/Ara-C/ATRA                                                                                                           CR                   YES (CNS + bone marrow)\      **ATRA + ATO + TIT---CR2**, alloHSCT planned                                          planned (haplo-identical)   11+
                                                                                                       NPM1-RAR~α~                                                                                                                                                                                                                                                         at 9 months                                                                                                                                     

  M/74                       1.7         No                                   NO              0        t(5;17)(q35;q21)\      **Induction** FLUGA → RES\                                                                                                                                                                                              RES                  NO                            \-                                                                                    NO                          24+
                                                                                                       NPM1-RAR~α~            2nd line AIDA → PR\                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                              3rd line IA 2+5 → CR, **Consolidation** intermediate-dose Ara-C (×2)                                                                                                                                                                                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M: male, F: female, NA: not available, CR: complete response, WBC: leukocytes, APL: acute promyelocytic leukemia, PCR: polymerase chain reaction, RES: resistance, PR: partial response, PLZF: promyelocytic leukaemia zinc finger, PETHEMA: Programa para el Tratamiento de Hemopatias Malignas, MTX: methotrexate, MRD: matched related donor, alloHSCT: allogeneic hematopoietic stem cell transplantation, MUD: matched unrelated donor, CNS: central nervous system, TIT: triple intrathecal therapy, ith: intratheca:, RTH: radiotherapy, s.c.: subcutaneous, ATRA: all-trans-retinoic acid, IDA: idarubicin, 6-MP: 6 mercaptopurine, 6-TG: 6- thioguanine, MTX: methotrexate, Ara-C: citarabine, HD-Ara-C: high dose Ara-C, MTZ: Mitoxantrone, ATO: arsenic trioxide, AIDA (IDA12 mg/m^2^ days 2, 4, 6, and 8, ATRA 45 mg/m^2^ till CR), IDICE (IDA 12 mg/m^2^ day 1, 3 and 5, Ara-C 500 mg/m^2^/12 h days 1, 3, 5, and 7, Etoposide 100 mg/m^2^ days 1, 2 and 3), DA 3+7 (Daunorubicin 60 mg/m^2^ days 1--3, Ara-C 200 mg/m^2^/12 h days 1--7), IA 3+7 (IDA 12 mg/m^2^ days 1--3, Ara-C 200 mg/m^2^/12 h days 1--7), AML-BFM 2004 INTERIM: induction AIE (Ara-C 100 mg/m^2^/24 h days 1--2, Ara-C 100 mg/m^2^/12 h days 3--8, Ida 12 mg/m^2^ days 3,5 and 7, Etoposide 150 mg/m^2^ days 6--8) plus ith Ara-C days 1 and 8, consolidation AI (Ara-C 500 mg/m^2^/24 h days 1--4, Ida 7 mg/m^2^ days 3, 5) plus ith Ara-C days 0 and 6, consolidation HAM (HD-Ara-C 1 g/m^2^/12 h days 1--3, MTZ 10 mg/m^2^ days 3--4) plus ith Ara-C days 0 and 6, intensification HAE (HD-Ara-C 3 g/m^2^/12 h days 1--3, ETO 125 mg/m^2^, days 2, 3, 4, 5) plus ith Ara-C day 0, maintenance (6-TG 40 mg/ m^2^ daily, Ara-C 40 mg/m^2^ s.c., for 4 days, every 4 weeks) plus ith Ara-C and RTH CNS 15 Gy, HD-Ara-C and ith Ara-C doses are modified according to age. FLUGA (Fludarabine 25 mg/m²/d i.v. days 26--, Ara-C 75 mg/m²/d i.v. days 2--5, g-CSF 5 µgr/kg/d s.c. days 1--3), FLAG-IDA (fludarabine 30 mg/m^2^, AraC 2 g/m^2^ for 5 days, idarubicin 10 mg/m^2^ for 3 days, and G-CSF 5 micro g/kg from day +6 until neutrophil recovery).

cancers-12-01313-t002_Table 2

###### 

Characteristics and clinical outcomes in patients reported with PLZF-RARa.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cases/First Reference                              Karyotype                                                          Sex/Age (Years)   WBC (×10^9^/L)         Response to ATRA-Containing Regimen            Response to ATO-Containing Regimen                                                                                    Induction(s) and Response(s)                                                                          Relapse\                                               AlloHSCT                Survival in Months (Status)
                                                                                                                                                                                                                                                                                                                                                                                                                                            (Months)\                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                            Salvage Therapy                                                                
  -------------------------------------------------- ------------------------------------------------------------------ ----------------- ---------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------ ----------------------- -----------------------------------
  **ATRA monotherapy induction**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B63-cancers-12-01313]\]                        46,XY,t(11;17)(q23;q21)                                            M/67              4.1                    Differentiation                                \-                                                                                                                    **Induction** ATRA---**ED**                                                                           \-                                                     \-                      0.7 (death)

  \[[@B11-cancers-12-01313]\]                        46,XY,t(11;17)(q23;q21)                                            F/81              7.6                    Differentiation                                \-                                                                                                                    **Induction** ATRA---**ED**                                                                           \-                                                     \-                      0.6 (death, cerebral bleeding)

  46,XY,t(11;17)(q23;q21)                            M/67                                                               4.1               Not evaluable          \-                                             **Induction** ATRA---**ED**                                                                                           \-                                                                                                    \-                                                     0.5 (death)             

  \[[@B7-cancers-12-01313]\]                         46,XX,t(11;17)(q23;q21);47,idem,+22                                F/48              42.5                   Not evaluable                                  \-                                                                                                                    **Induction** ATRA---**ED**                                                                           \-                                                     \-                      0.3 (death by cerebral bleeding)

  \[[@B34-cancers-12-01313]\]                        46,XY, t(11;17)(q23;q21) with del(5)(q22q35)                       M/53              15.4                   NO                                             \-                                                                                                                    **Induction** ATRA---**RES**, DNR + Ara-C---**CR**                                                    NA                                                     NA                      NA

  **ATRA + chemotherapy-based induction**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  \[[@B12-cancers-12-01313]\]                        46,XY,t(11;17)(q23;q21)                                            M/31              69.5                   YES                                            \-                                                                                                                    **Induction** ATRA + Ara-C + IDA (3+7)---**CR**, **Consolidation** Ara-C + amsacrine, ETO + MTZ       YES (11)\                                              YES\                    51+
                                                                                                                                                                                                                                                                                                                                                                                                                                            ATRA---**CR2**, consolidation HD-Ara-C, **alloHSCT**   in CR2                  

  \[[@B13-cancers-12-01313]\]                        46,XY,t(11;17)(q23;q21)                                            M/83              NA                     YES                                            \-                                                                                                                    **Induction**: ATRA + DNR---**CR Consolidation** DNR + Ara-C × 2, **Maintenance** ATRA +6-MP + MTX    NO                                                     NO                      24+

  \[[@B49-cancers-12-01313]\]                        47,XY,+8/47,XY,+8,t(11;17)(q23;q21)                                M/62              1.2                    YES                                            \-                                                                                                                    **Induction** ATRA + ADE---**CR**                                                                     YES (7)\                                               NO                      17+
                                                                                                                                                                                                                                                                                                                                                                                                                                            NA                                                                             

  \[[@B10-cancers-12-01313]\]                        46,XY,t(11;17)(q23;q21)/46,XY                                      M/53              4.5                    YES                                            \-                                                                                                                    **Induction** ATRA + ADE---**CR**, **Consolidation** ADE, MACE, MiDAC                                 YES (45)\                                              YES\                    177+
                                                                                                                                                                                                                                                                                                                                                                                                                                            FLAG × 2 + ATRA---**CR2, alloHSCT**                    in CR2                  

  \[[@B26-cancers-12-01313]\]                        46,XY,t(7;17)(q35;q21)                                             M/58              7.4                    YES                                            \-                                                                                                                    **Induction** ATRA + DAT---**CR**, **Consolidation** DAT + ATRA, MACE                                 YES (36)\                                              NO                      36 (death in relapse)
                                                                                                                                                                                                                                                                                                                                                                                                                                            NA                                                                             

  \[[@B8-cancers-12-01313]\]                         46,XY,t(11;17)(q23;q21)/45,X,-Y,t(11;17)(q23;q21)                  M/50              6.8                    YES                                            \-                                                                                                                    **Induction** ATRA + ADE---**CR**, **Consolidation** ADE, MACE, MiDAC                                 NO                                                     NO                      73+

  \[[@B3-cancers-12-01313]\]                         46,XY, t(11;17)(q23;q21)/46,idem,del(12)(p1?)/46,idem,-6,+r        M/75              2.0                    YES                                            \-                                                                                                                    **Induction** ATRA + DAT---**CR**, **Consolidation** DAT, MACE                                        YES (55)\                                              NO                      88 (death in CR2)
                                                                                                                                                                                                                                                                                                                                                                                                                                            DNR + Ara-C---**CR2**                                                          

  \[[@B3-cancers-12-01313]\]                         45,X,2Y,t(11;17)(q23;q21)                                          M/32              11.6                   YES                                            \-                                                                                                                    **Induction** AIDA---**CR, alloHSCT**                                                                 NO                                                     YES\                    37+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   in CR1                  

  46,XY,i(7)(q10),t(11;17)(q23;q21)                  M/43                                                               10.4              YES                    \-                                             **Induction** AIDA---**CR**                                                                                           YES (30)\                                                                                             NO                                                     30 (death in relapse)   
                                                                                                                                                                                                                                                                                                                                      NO                                                                                                                                                                                   

  \[[@B28-cancers-12-01313]\]                        46,XY,t(11;17)(q23;q21)/47,idem,+8                                 M/68              6.9                    Differentiation (monotherapy in second line)   \-                                                                                                                    **Induction**: ATRA + DNR + Ara-C---**RES**, ATRA (monotherapy)---**RES**, MTZ + HD-Ara-C---CR        YES (15)\                                              NO                      15 (death in relapse)
                                                                                                                                                                                                                                                                                                                                                                                                                                            NO                                                                             

  \[[@B11-cancers-12-01313]\]                        45,X,2Y,add(2)(q33),t(11;17)(q23;q21)/46,XY                        M/34              2.4                    NO                                             \-                                                                                                                    **Induction** ATRA + DNR + Ara-C---**RES**, Amsacrine + HD-Ara-C---**CR**                             YES (56)\                                              NO                      57 (death in relapse)
                                                                                                                                                                                                                                                                                                                                                                                                                                            NO                                                                             

  \[[@B14-cancers-12-01313]\]                        No metaphases                                                      M/48              71.6                   NO                                             NO (in second line)                                                                                                   **Induction** ATRA + DNR × 2---**RES**, HIDAC + ATO---**RES**                                         \-                                                     \-                      NA

  \[[@B14-cancers-12-01313]\]                        46,XX,t(11;17)(q23;q22)                                            F/38              23.6                   NO                                             \-                                                                                                                    **Induction** ATRA + DNR---**RES**, MTZ + ETO + Ara-C---**ED**                                        \-                                                     \-                      2 (death by sepsis)

  \[[@B32-cancers-12-01313]\]                        46,XX,add(17)(q21)\[4\]/46,XX\[9\]. ish der(11)t(11;17)(q23;q21)   M/81              1.8                    Not evaluable                                  \-                                                                                                                    **Induction** AIDA---**ED**                                                                           \-                                                     \-                      0.3 (death by pulmonary bleeding)

  **Chemotherapy-based induction**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  \[[@B11-cancers-12-01313]\]                        46XY+(3)+(13)(q34), t(11;17)(q23;q21)                              M/53              15.3                   \-                                             \-                                                                                                                    **Induction** DNR + Ara-C---**CR**\                                                                   YES (7)\                                               NO                      28 (death in relapse)
                                                                                                                                                                                                                                                                                                                                      **Consolidation** DNR + Ara-C                                                                         DNR + Ara-C + Gm-CSF---**CR2**\                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                            2nd relapse (19)\                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                            ETO + MTZ---**CR3**\                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                            ATRA + other---**RES**\                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                            3nd relapse (23)                                                               

  \[[@B31-cancers-12-01313]\]                        t(11;17)(q23;q21)                                                  M/52              1.6                    \-                                             \-                                                                                                                    **Induction** chemotherapy---**CR**                                                                   NA                                                     NA                      NA

  \[[@B29-cancers-12-01313]\]                        46,XY,t(11;17)(q23;q21)                                            M/37              45.2                   \-                                             \-                                                                                                                    **Induction** DNR + Ara-C---**RES**, IFN-alpha---**RES**, ETO + MTZ---**CR**                          NO                                                     NO                      11 (death cause unknown)

  \[[@B3-cancers-12-01313]\]                         46,XY,t(11;17)(q23;q21),idem,-Y/46,XY                              M/34              20                     YES (in second line)                           \-                                                                                                                    **Induction** DNR + Ara-C + ETO---**RES**, Ara-C + IDA+ATRA---**CR, alloHSCT**                        NO                                                     YES\                    33+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   in CR1                  

  \[[@B33-cancers-12-01313]\]                        t(11;17)(q23;q21)                                                  M/50              1.3                    YES (in second line)                           YES (in second line)                                                                                                  **Induction** DNR + Ara-C---**RES**, ATRA + ATO---**CR**                                              NA                                                     NA                      NA

  \[[@B3-cancers-12-01313]\]                         46,XY.ish,ins(11;17)(q23;q21,q21)                                  M/62              9.9                    YES (monotherapy at relapse)                   \-                                                                                                                    **Induction** Ida + Ara-C + ETO---**RES**, MICE---**CR**                                              YES\                                                   NO                      25 (death in relapse)
                                                                                                                                                                                                                                                                                                                                                                                                                                            ATRA-**CR2**\                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                            2nd relapse (8)---no treatment                                                 

  **ATO+ATRA+/-chemotherapy-based induction**                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  \[[@B7-cancers-12-01313]\]                         46,XX,der(11),der(17)/46,XX                                        F/60              34                     YES                                            YES                                                                                                                   **Induction** ATRA + ATO + IDA---**CR**, **Consolidation** ATO + IA, MTZ, ATO + DNR, ATO + DA, MA     NO                                                     NO                      11 +

  46,XY,?t(11;17)(q23;q21)/46,XY                     M/44                                                               52.1              NO                     NO                                             **Induction** ATRA + DNR + Ara-C (3+7) + ATO---**RES**                                                                \-                                                                                                    \-                                                     5+                      

  47,XY,+8\[4/20\]/47,idem,t(11;17)(q23;q21)/46,XY   M/52                                                               8.9               YES (in second line)   NO                                             **Induction** ATRA+ATO---**RES**, DNR + ATRA + CAG × 3---**CR**                                                       NO                                                                                                    NO                                                     7+                      

  46,XX,t(11;17)(q23;q22)/46,XY                      M/46                                                               23.1              NO                     NO                                             **Induction** ATRA + ATO---**RES**, IDA + Ara-C---**CR**, **Consolidation** MTZ + ETO + Ara-C, MTZ + Ara-C, HD-AraC   NO                                                                                                    NO                                                     5+                      

  **ATO+/-chemotherapy-based induction**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  \[[@B9-cancers-12-01313]\]                         45,X,-Y, t(11;17)(q23;q21)/46,XY, t(11;17)(q23;q21)                M/23              9.1                    \-                                             NO                                                                                                                    **Induction** ATO---**RES**, DNR + Ara-C 3+7---**CR**; **Consolidation** Ara-C × 5, Ara-C + DNR × 4   YES (7)\                                               NO                      32+
                                                                                                                                                                                                                                                                                                                                                                                                                                            NA                                                                             

  \[[@B30-cancers-12-01313]\]                        NA                                                                 M/15              64.9                   \-                                             NO                                                                                                                    **Induction** ATO + IDA---**RES**, HD-Ara-C (×3)---**CR**, **Maintenance** ATRA                       NO                                                     NO                      NA

  NA                                                 M/38                                                               NA                \-                     NO                                             **Induction** ATO---**RES**                                                                                           \-                                                                                                    \-                                                     2+                      

  NA                                                 M/45                                                               NA                \-                     NO                                             **Induction** ATO---**RES**                                                                                           \-                                                                                                    \-                                                     NA                      

  NA                                                 M/36                                                               4.9               \-                     NO                                             **Induction** ATO + Decitabine---**RES**, DNR + Ara-C---**RES**, HD-Ara-C---**CR, Consolidation** HD-Ara-C × 2        YES (11)\                                                                                             NO                                                     11 (death in relapse)   
                                                                                                                                                                                                                                                                                                                                      NO                                                                                                                                                                                   

  NA                                                 M/22                                                               76.9              \-                     NO                                             **Induction** ATO---**RES**, HD-Ara-C (×3)---**NA**                                                                   NA                                                                                                    NA                                                     NA                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M: male, F: female, NA: not available, WBC: leukocytes, CR: complete response, RES: resistance, ED: early death, alloHSCT: allogeneic hematopoietic stem cell transplantation, ATRA: all-trans-retinoic acid, ATO: arsenic trioxide, G-CSF: Granulocyte colony-stimulating factor, DNR: daunorubicine, IDA: idarubicin, Ara-C: cytarabine, HD-Ara-C: high dose Ara-C, IFN: interpherone, ETO: etoposide, MTZ: Mitoxantrone, MTX: mitoxantrone, 6-MP: 6-mercaptopurinum, MACE (Amsacrine, Ara-C, Etoposide), MiDAC (mitoxantrone, Ara-C), IA (Ida plus Ara-C), FLAG (fludarabine, Ara-C, G-CSF), MA (Mitoxantrone, Ara-C), CAG (Ara-C, aclarubin and G-CSF), MICE (Ara-C, Etoposide, Gemtuzumab ozogamicin, Ida, Mitoxantrone), AIDA (ATRA plus IDA), ADE (Ara-C, ADR plus ETO), DAT (DNR, Ara-C plus thioguanine), DA (DNR plus Ara-C)

cancers-12-01313-t003_Table 3

###### 

Characteristics, treatment, and outcomes of 9 NPM1-RARa APL patients reported in the literature.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case Reference                                                 Karyotype                                                                                              Sex/Age (Years)   WBC (×10^9^/L)   Myeloid Sarcoma   Response to ATRA-Containing Regimen   Response to ATO-Containing Regimen          Induction and Response                                                                                                        Relapse (Months)\                  alloHSCT                                  Survival in Months (Status)
                                                                                                                                                                                                                                                                                                                                                                                                                                             Salvage Therapy                                                              
  -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------------- ---------------- ----------------- ------------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ----------------------------------------- ------------------------------------
  \[[@B37-cancers-12-01313],[@B40-cancers-12-01313]\]            46,XX,t(5;17)(q32;q12) 48,XX,t(5;17),+2mar                                                             F/2               NA               NO                YES                                   \-                                          **Induction** DNR + Ara-C + ETO---**CR**, then ATRA---**molecular CR,** autoHS**CT**                                          YES (7)                            NO\                                       7 (death in relapse)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                (autoHSCT)                                

  \[[@B41-cancers-12-01313]\]                                    47,XY,t(5;17)(q35;q21),der(8)(p23), der(10)(q26),del(12)(q13q22),del(1)(q12q14),−16,−18,+21,+22,+mar   M/12              NA               NO                YES                                   \-                                          **Induction** DNR + Ara-C (3+7)---**CR**, consolidation DNR + Ara-C + 6-TG + ETO + DXM                                        YES (5)\                           YES in CR2                                8+
                                                                                                                                                                                                                                                                                                                                                                                                                                             ATRA + Ara-C---**CR2**, alloHSCT                                             

  \[[@B3-cancers-12-01313]\]                                     46,XX,ins(3;5)(q26;q13q13),t(5;17)(q34;q21)                                                            F/9               17               NO                YES                                   \-                                          **Induction** ATRA + Ara-C + MTZ---**CR**, consolidation DNR + Ara-C + ETO                                                    NO                                 NO                                        29+

  46,XX,der(5)t(5;17)(q13;q21),del(8)(q22q24),der(17),532--dim   F/76                                                                                                   43.1              NO               YES               \-                                    **Induction** ATRA + DNR + Ara-C---**ED**   \-                                                                                                                            \-                                 0.5 (death by differentiation syndrome)   

  \[[@B6-cancers-12-01313]\]                                     46,XY,t(5;17)(q35;q21),del(12)(p13)                                                                    M/12              15.7             NO                Not evaluable                         \-                                          **Induction** ATRA---**ED**                                                                                                   \-                                 \-                                        0.2 (death by cerebral hemorrhage)

  \[[@B39-cancers-12-01313]\]                                    46,XY,t(5;17)(q35;q21)                                                                                 M/29              2.9              Pelvis            YES                                   NA (used in relapse)                        **Induction** AIDA---**CR** consolidation IDA + Ara- + ATRA), MTZ + ETO + ATRA, IDA + Ara-C + 6-TG + ATRA, maintenance ATRA   YES (22)\                          NO                                        23+
                                                                                                                                                                                                                                                                                                                                                                                                                                             ATO (1 cycle)                                                                

  \[[@B36-cancers-12-01313]\]                                    46,XY,t(5;17)(q35;q12)\[4\]/46,XY\[16\]                                                                M/4               NA               Skin              YES                                   \-                                          **Induction** ATRA + chemotherapy---**CR**                                                                                    YES (NA)                           NO                                        46+

  \[[@B38-cancers-12-01313]\]                                    46,XY,t(5;17)(q35;q12)                                                                                 M/51              4.2              Vertebral         YES                                   \-                                          **Induction** ATRA + chemotherapy---**CR**                                                                                    NO                                 NO                                        2+

  \[[@B35-cancers-12-01313]\]                                    46,XY,t(5;17)(q35;q12)                                                                                 M/64              NA               No                Yes                                   \-                                          **Induction** ATRA + chemotherapy---**CR**                                                                                    NO                                 NO                                        18+
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Ref: references, M: male, F: female, NA: not available, CR: complete response, ED: early death, alloHSCT: allogeneic hematopoietic stem cell transplantation, autoHSCT: autologous hematopoietic stem cell transplantation, DIC: disseminated intravascular coagulopathy, ATRA: all-trans-retinoic acid, ATO: arsenic trioxide, Ara-C: cytarabine, DNR: daunorubicine, IDA: idarubicin, 6-TG: 6-thioguanine, ETO: etoposide, DXM: dexamethasone, MTZ: Mitoxantrone.

cancers-12-01313-t004_Table 4

###### 

Cases reported in the literature with other variant APL.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                                                                                                                                                                                                                                                   Rearrangement                                Karyotype                                                                    N of Cases   Sex/Median Age Years (Range)                   WBC × 10^9^/L Median\          ATRA Sensitivity   ATO Sensitivity                            Treatment Schedules                                                                                                                                 Relapse Months                                                           HSCT                                     OS (Months)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (Range)                                                                                                                                                                                                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------------- ------------ ---------------------------------------------- ------------------------------ ------------------ ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------- -------------------------------------------------------------------------
  \[[@B8-cancers-12-01313],[@B15-cancers-12-01313],[@B16-cancers-12-01313],[@B17-cancers-12-01313],[@B18-cancers-12-01313],[@B19-cancers-12-01313],[@B20-cancers-12-01313],[@B21-cancers-12-01313],[@B22-cancers-12-01313],[@B23-cancers-12-01313],[@B24-cancers-12-01313]\]   STAT5B-RAR~α~                                From normal till complex karyotype, (interstitial deletion within chr. 17)   12           M (10)/F (3)\                                  16.1\                          YES                POSSIBLE\                                  IA, ETO, FLAG, CAG, FLA, DA, MTZ, GO, Decitabine, ATO (most of them with ATRA)---**CR in 8/12 (67%)** cases (5 CR with ATRA-containing induction)   YES (4 patients)\                                                        YES\                                     Median 25.6\
                                                                                                                                                                                                                                                                                                                                                                                                                      42 (17--67) years                              (2.1--77.8)                                       1 CR with ATRA + ATO + Ida                                                                                                                                                                     Median 30.4, range 3.5--56                                               2 in CR1 and 2 in CR2                    (0--75)

  \[[@B43-cancers-12-01313],[@B44-cancers-12-01313],[@B45-cancers-12-01313],[@B46-cancers-12-01313]\]                                                                                                                                                                          TBLR1-RAR~α~ (1 case also with PML-RAR~α~)   t(3;17)(q26;q12--21) plus other alterations\                                 6            M (6)/F (2)\                                   14.1 and 20.4 (available)      YES                POSSIBLE (in 2nd line with chemotherapy)   [1st case]{.ul}: ATRA + DNR---**CR**,\                                                                                                              YES (2 patients after 10 and 24 months; one extramedullary)              YES (1 patient in 2nd CR---cord blood)   1 patient alive after alloHSCT
                                                                                                                                                                                                                                                                                                                            t(3;17)\                                                                                  41.3 (3--72) years (available in 4 patients)                                                                                                [2nd case]{.ul}: ATRA + MTZ---**RES**,\                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                            (p25;q21) in 1 case                                                                                                                                                                                                                   [3rd case]{.ul}: ATRA + chemotherapy---**ED**\                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [4th case:]{.ul} ATRA---**RES**\                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [5th case]{.ul}: ATRA---**RES**, chemotherapy **CR**\                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [6th case]{.ul}: ---**ED**                                                                                                                                                                                                                                            

  \[[@B47-cancers-12-01313],[@B48-cancers-12-01313],[@B49-cancers-12-01313],[@B50-cancers-12-01313],[@B51-cancers-12-01313]\]                                                                                                                                                  IRF2P2-RAR~α~                                Normal, diploid, −X (2 cases), t(1;17)(q42;q21)                              5            M(2)/F (3)\                                    3.8\                           YES                YES                                        [1st case]{.ul}: ATRA + ATO + GO---**CR**/[2nd case]{.ul}: ATRA + IDA + Ara-C + GO---**CR**\                                                        YES (3 patients between 8--12 months)                                    1 patient (after relapse)                Median 39 (8--18) months
                                                                                                                                                                                                                                                                                                                                                                                                                      38 (19--68) years                              (1.65--5.14)                                                                                 [3rd case]{.ul}: ATRA---**CR**\                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [4th case]{.ul}: ATRA + IDA + Ara-C---**CR**\                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [5th case]{.ul}: ATRA + ATO + DRN + Ara-C---**CR**                                                                                                                                                                                                                    

  \[[@B52-cancers-12-01313],[@B53-cancers-12-01313]\]                                                                                                                                                                                                                          FIP1L1-RAR~α~                                t(4;17)(q12;q21)                                                             2            F (2)\                                         59 in 1 case (other case NA)   YES                \-                                         [1st case:]{.ul}**Induction** AIDA protocol---**ED**;\                                                                                              NA                                                                       NO                                       1st patient: 0.3 (death by DS), 2nd patient NA
                                                                                                                                                                                                                                                                                                                                                                                                                      77, 90                                                                                                                                      [2nd case]{.ul}: **Induction** ATRA---**CR**                                                                                                                                                                                                                          

  \[[@B54-cancers-12-01313]\]                                                                                                                                                                                                                                                  STAT3-RAR~α~                                 45,XY,-Y\[6\]/46,XY\[8\] or 46,XY\[20\]                                      2            M (2)\                                         6.6, 32.3                      NO                 NO                                         [1st case:]{.ul}\                                                                                                                                   YES (1st patient)                                                        NO                                       1st patient: 33 (death in relapse), 2nd patient 6 months (death as RES)
                                                                                                                                                                                                                                                                                                                                                                                                                      24, 26                                                                                                                                      **Induction** ATO + ATRA---**RES**, DA3+7---**RES**,\                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Homoharringtonine + ARA-C + G-CSF---**CR**, consolidation FLU + ARA-C (×4) MTZ + ARA-C (×1)\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [2nd case:]{.ul} **Induction** ATRA---**RES**, IA3+7---**RES**                                                                                                                                                                                                        

  \[[@B55-cancers-12-01313],[@B58-cancers-12-01313]\]                                                                                                                                                                                                                          BCOR-RAR~α~                                  t(X;17)(p11;q21) or\                                                         2            M/45 and 71                                    25.3 and \>10                  YES                NO (in relapse)                            [1st case:]{.ul}**Induction** ATRA + IDA + Ara-C---**CR**, than **Consolidation**\                                                                  YES at 35 months\                                                        YES (cord blood\                         44+ and 12+
                                                                                                                                                                                                                                                                                                                            Y,t(X;17)(p11.4;q21)                                                                                                                                                                                                                  [2nd case:]{.ul}**Induction** DA 3+7---**CR**, **Consolidation** ATRA + chemotherapy                                                                IDA + Ara-C + ATRA---**CR2**\                                            in 3rd CR)                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      2nd at 41 months---ATO---**RES**, tamibarotene + DNR + Ara-C---**CR3**                                            

  \[[@B56-cancers-12-01313]\]                                                                                                                                                                                                                                                  GTF2I-RAR~α~                                 t(7;17)(q11;q21)                                                             1            M/35                                           53.7                           No                 NO                                         **Induction** ATRA + DA - **RES**\                                                                                                                  \-                                                                       \-                                       4.8 (death as RES)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ID-ARA-C -- **RES**\                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  IAH -- **RES**\                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ATRA+ATO -- **RES**, death                                                                                                                                                                                                                                            

  \[[@B57-cancers-12-01313]\]                                                                                                                                                                                                                                                  NuMa1-RAR~α~                                 t(11;17)(q13;q21)                                                            1            M/0.5                                          3.6                            YES                \-                                         **Induction** ATRA---**CR**, autoHSCT                                                                                                               NO                                                                       NO (autoHSCT)                            38

  \[[@B59-cancers-12-01313]\]                                                                                                                                                                                                                                                  PRKAR1A-RAR~α~                               t(17;17)(q21;q24)                                                            1            M/66                                           5.3                            YES                YES                                        **Induction** ATRA + ATO + IDA---**CR**, Consolidation Ara-C + amsacrine × 3, Maintenance ATRA                                                      NO                                                                       NO                                       24+

  \[[@B60-cancers-12-01313]\]                                                                                                                                                                                                                                                  NABP1-RAR~α~\                                der(2)(t(2;17)(q32;q21) with sublcones t(11;19)(q13;p13.1)                   1            M/59                                           96.9                           YES                \-                                         **Induction** AIDA---**CR** Consolidation × 2 cycles                                                                                                NO                                                                       YES (MUD)                                15+
                                                                                                                                                                                                                                                                               (OBFC2A-RAR~α~)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  \[[@B62-cancers-12-01313]\]                                                                                                                                                                                                                                                  TFG-RAR~α~                                   t(3;14;17)(q12;q11;q21)                                                      1            M/16                                           1.81                           YES                                                           **Induction**: ATRA---**CR, Consolidation**: ATRA + IDA (×2), **maintenance**: ATRA                                                                 NO                                                                       NO                                       NA

  \[[@B61-cancers-12-01313]\]                                                                                                                                                                                                                                                  FNDC3B-RAR~α~                                t(3;17)(q26;q21)                                                             1            M/36                                           3.6                            YES                \-                                         **Induction** ATRA + DA 3+7---**CR**, consolidation DA 5+2, HD-Ara-C, maintenance ATRA/MTX/6-MP                                                     YES                                                                      NO                                       8 (death in relapse)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ref: references, N: number, M: male, F: female, WBC: leukocytes, CR: complete response, RES: resistance, OS: overall survival, ED: early death, HSCT: hematopoietic stem cell transplantation, allo: allogenic, auto: autologous, DS: differentiation syndrome, ATRA: all-trans-retinoic acid, ATO: arsenic trioxide, GO: gentuzumab ozogamizine; ETO: etoposide, IDA: idarubicine, DNR: daunorubicine, G-CSF: Granulocyte colony-stimulating factor, MTZ: mitoxantrone, FLU: fludarabine, MTX: metotrexate, MTZ: mitoxantrone, 6-MP: 6-mercaptopurine, ID-Ara-C: intermediate dose Ara-C, IA/IA 3+7: Ida plus Ara-C, DA: DNR plus Ara-C, FLA: fludarabine plus Ara-C, FLAG: fludarabine, Ara-C, G-CSF, CAG: Ara-C, aclarubin, G-CSF, AIDA: ATRA plus IDA, IAH: Ida plus Ara-C plus homoharringtonine.
